Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis

Abstract

Background

To evaluate the prognostic role of interleukin-6 (IL-6) in renal cell carcinoma (RCC).

Method

Relevant research articles were obtained from literature databases. Data were extracted from study reports which reported IL-6 levels in relevance to RCC prognosis and random-effects meta-analyses were performed to estimate IL-6 levels, percentage of patients with high IL-6 levels, and hazard/odds ratios between high and low IL-6 levels in survival outcomes.

Results

22 studies (1976 patients; age 59.9 years [95% confidence interval (CI) 58.0, 61.8]; 33% [95% CI 29, 36] females) were included. IL-6 levels in RCC patients ranged from 8.9 ± 13–193 ± 101 picograms per milliliter (pg/ml) which were higher than those of normal healthy individuals (mean difference 13.96 pg/ml [95% CI: 1.52, 26.40]; p = 0.03). Percentage of RCC patients with high IL-6 levels was 48.98% [95% CI 42.94, 55.03] and this rate was greater in advanced (51.73% [95% CI 45.94, 57.53]) than in local (40.75% [95% CI 26.23, 55.27]) RCC. Survival was longer in patients with low compared to high IL-6 levels (MD 9.65 months [95% CI 5.01, 14.29]; p < 0.0006 and hazard ratio 3.03 [95% CI 2.37, 3.70]). Treatment response rate was significantly higher in patients with low IL-6 than high IL-6 levels (odds ratio 5.11 [95% CI 2.21, 11.77]; p < 0.00001). There was a strong correlation between IL-6 and c-reactive protein levels (correlation coefficient 0.622 [95% CI 0.431, 0.760]; p = 0.00001).

Conclusion

IL-6 levels are much variable in RCC patients. High levels of IL-6 in RCC patients are associated with poor survival.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Ishibashi K, Koguchi T, Matsuoka K, et al. Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci. 2018;64:103–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84.

    PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–90.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Cho YH, Kim MS, Chung HS, Hwang EC. Novel immunotherapy in metastatic renal cell carcinoma. Investig Clin Urol. 2017;58(4):220–7.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016;50:109–17.

    PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Review of checkpoint inhibitors for the treatment of renal cell carcinoma. Curr Treat Options Oncol. 2017;18(1):7. https://doi.org/10.1007/s11864-017-0458-0.

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, Zastrow S, Miller K. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179–88.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  8. 8.

    Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–63.

    PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Shinohara N, Nonomura K, Abe T. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci. 2012;103(9):1695–700.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Okita K, Hatakeyama S, Tanaka T, et al. Impact of disagreement between two risk group models on prognosis in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2019. https://doi.org/10.1016/j.clgc.2019.01.00.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–39.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  14. 14.

    Ghandadi M, Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. Curr Pharm Des. 2016;22(5):518–26.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    Alberti L, Thomachot MC, Bachelot T, et al. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer. 2004;111:653–61.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Costes V, Liautard J, Picot MC, et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J Clin Pathol. 1997;50:835–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Dosquet C, Schaetz A, Faucher C, et al. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer. 1994;30A:162–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Falkensammer CE, Thurnher M, Leonhartsberger N, et al. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int. 2011;107:1893–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Fu Q, Chang Y, An H, et al. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5 year conditional cancer-specific survival analysis. Br J Cancer. 2015;113:1581–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Fumagalli L, Lissoni P, Di Felice G, et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer. 1999;80:407–11.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Hrab M, Olek-Hrab K, Antczak A, et al. Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC). Rep Pract Oncol Radiother. 2013;18:304–9.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Kallio J, Hämäläinen M, Luukkaala T, et al. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. Urol Oncol. 2017;35:544.e25–31.

    CAS  Article  Google Scholar 

  24. 24.

    Kim CS, Kim Y, Kwon T, et al. Regulatory T cells and TGF-β1 in clinically localized renal cell carcinoma: comparison with age-matched healthy controls. Urol Oncol. 2015;33(113):e19–25.

    Google Scholar 

  25. 25.

    Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer. 1997;33:1794–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the groupe francais d’immunotherapie. J Clin Oncol. 2004;22:2371–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Pilskog M, Bostad L, Edelmann RJ, et al. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. J Pathol Clin Res. 2018;4:114–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Polimeno M, Napolitano M, Costantini S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int. 2013;112:686–96.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Ramsey S, Aitchison M, Graham J, et al. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int. 2008;102:125–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst. 1992;84:1835–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Thiounn N, Pages F, Flam T, et al. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997;58:121–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13:827–37.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol. 1992;148(6):1778–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Walther MM, Johnson B, Culley D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1 beta in patients with renal cell carcinoma. Br J Cancer. 2002;86:1396–400.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Zurita AJ, Jonasch E, Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012;23:46–52.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Rossi JF, Négrier S, James ND, et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Angevin E, Tabernero J, Elez E, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:2192–204.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012;48:85–93.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Ishibashi K, Koguchi T, Matsuoka K, et al. Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci. 2018;64:103–10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Mizutani Y, Bonavida B, Koishihara Y, et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995;55:590–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Fitzgerald JP, Nayak B, Shanmugasundaram K, et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One. 2012;7:e30712.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    An H, Zhu Y, Xie H, et al. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Tumour Biol. 2016;37:4523–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Pan D, Xu L, Liu H, et al. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Sci. 2015;106:592–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Ito H, Shioi K, Murakami T, et al. C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer. 2012;12:337.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Funding

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Y. Wang.

Ethics declarations

Conflict of interest

All the authors have declared that they have no conflict of interest.

Research involving human participants and/or animals

All analyses were based on previous published studies, thus no ethical approval required.

Informed consent

For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Zhang, Y. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clin Transl Oncol 22, 835–843 (2020). https://doi.org/10.1007/s12094-019-02192-x

Download citation

Keywords

  • Renal cell carcinoma
  • Interleukin-6
  • Prognosis
  • Metastasis
  • Survival